[Skip to content]

Cancer Advice - from leading UK Cancer Specialists
Find information
In this section...
On this site...

Intraperitoneal radio-immunotherapy in ovarian cancer

A murine monoclonal antibody, that recognises a repeated epitope of a tumour associated antigen present on the surface of over 90% of ovarian cancer cells, has been used as therapy by instillation into the peritoneal cavity (the abdominal cavity) of patients with the common clinical problem of ascitic (fluid) filled abdominal relapse of ovarian cancer.
The theory is that the antibody coats the walls of the abdominal cavity and all the other surfaces (e.g. gut and other organs) in the cavity and destroys the thin lining of cancer cells that have shed off the ovarian cancer and taken root there. Unfortunately, to date, the results using a particular antibody called HMFG1 do not look promising.